Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Avastin Top-Seller in Japan for 2nd Straight Month in September: Encise Snapshot
October 11, 2018
- Perjeta Gets Japan OK as Neoadjuvant, Adjuvant Therapy for HER2 Breast Cancer
October 11, 2018
- Shonan iPark to Focus on Disease Prevention, 3 Other Areas, Aiming to House 200 Companies by FY2023
October 11, 2018
- Towa’s Allegra Generic Grabs Approval for Expanded Pediatric Use
October 11, 2018
- Opdivo/Yervoy Combo Gets 1st Line RCC Nod in South Korea
October 10, 2018
- Ethical Drug Sales Down 2.0% in August: Crecon
October 10, 2018
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- 3 Japan Major Pharmas to Launch 2nd Open Drug Reposition Program
October 10, 2018
- Funding Disclosures Reveal Changes in Money Flows; Biz Models, Pricing Reform Driving the Shift
October 9, 2018
- Osaka Univ. Spinout FunPep Raises 460 Million Yen
October 9, 2018
- Canada Approves Mitsubishi Tanabe’s ALS Med Radicava
October 9, 2018
- Belviq Reduces Risk of Progression to Type 2 Diabetes: Eisai
October 9, 2018
- Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
- Reldesemtiv Shows Efficacy for Spinal Muscular Atrophy in PII: Astellas/Cytokinetics
October 9, 2018
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- Fujifilm Develops New Technology to Search and Design Candidate Compounds Using Structural Formulas Alone
October 5, 2018
- Novo’s Oral GLP-1 Analogue Semaglutide Comparable to Subcutaneous Dulaglutide in No. of AEs: Japan PIIIa Study
October 5, 2018
- Blincyto OK Now in Hand, Amgen Astellas JV Revs Up for Foray into Japan Oncology Market
October 4, 2018
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…